Evidence map›Paper›PMID 39835546›Full record

ArticleRecent patents on biotechnology2026

Exploring the Therapeutic Potential of TROP2 Gene Silencing in Hepatocellular Carcinoma.

Fatma Yakoub, Hanem Hassan, Samah Mamdouh, Tarek Aboushousha, Fatma B Rashidi, Mohamed A El-Desouky

Abstract read
PubMed Publisher
In one paragraph

Article in Recent patents on biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fatma YakoubBiochemistry and Molecular Biology Department, Theodor Bilharz Research Institute, Giza, Egypt.
Hanem HassanBiochemistry and Molecular Biology Department, Theodor Bilharz Research Institute, Giza, Egypt.ORCID 0000-0002-1417-1412
Samah MamdouhBiochemistry and Molecular Biology Department, Theodor Bilharz Research Institute, Giza, Egypt.ORCID 0000-0001-5979-3189
Tarek AboushoushaDepartment of Pathology, Theodor Bilharz Research Institute, Giza, Egypt.ORCID 0000-0002-6686-2442
Fatma B RashidiBiochemistry Division, Chemistry Department, Faculty of Science, Cairo University, Giza, Egypt.
Mohamed A El-DesoukyBiochemistry Division, Chemistry Department, Faculty of Science, Cairo University, Giza, Egypt.ORCID 0000-0001-5007-5455

Funding

Theodor Bilharz Research Institute (TBRI), Giza, Egypt BC2191
6 · The paper itself

Abstract

backgroundTrophoblast Cell Surface Antigen 2 (Trop2) is a transmembrane glycoprotein that has been implicated in the progression and metastasis of various cancers, including hepatocellular carcinoma (HCC). Targeting Trop2 expression may represent a promising approach for the development of novel therapeutic strategies and patents.

objectivesThis study aimed to investigate the effects of Trop2 knockdown using small interfering RNA (siRNA) on the phenotypic and molecular characteristics of the HepG2 liver cancer cell line.

methodsHepG2 cells were transfected with different concentrations of Trop2-targeting siRNA (3 nM, 5 nM, and 7 nM) at various time intervals (6, 24, and 48 hrs). The expression of Trop2 was assessed by real-time PCR before and after transfection. The impact of Trop2 knockdown on cell apoptosis, migration, morphology, histopathological features, wound-healing assays, and microscopic analysis was examined. Additionally, the expression of the TPM1 gene was evaluated using immunohistochemical analysis.

resultsTrop2 mRNA level was significantly decreased in HepG2 cells in a time- and concentration-dependent manner following siRNA transfection. The downregulation of Trop2 resulted in a marked increase in apoptosis, a reduction in cell migration, and alterations in cell morphology and histopathological characteristics. Furthermore, the expression of the TPM1 gene was found to be upregulated in Trop2-knockdown HepG2 cells.

conclusionThese results highlight the potential of Trop2 as a therapeutic target for the management of hepatocellular carcinoma.

Indexed as

Antigens, NeoplasmCarcinoma, HepatocellularCell Adhesion MoleculesGene SilencingLiver NeoplasmsApoptosisCell MovementGene Expression Regulation, NeoplasticGene Knockdown TechniquesHep G2 CellsHumansPatents as TopicRNA, Small InterferingTropomyosinAntigens, NeoplasmCell Adhesion MoleculesRNA, Small InterferingTACSTD2 protein, humanTropomyosincell apoptosisHepatocellular carcinomaimmunohistochemical analysis.siRNATPM1Trop2

Identifiers

PMID39835546

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.